Phase II trial of carboplatin and etopos
β
John Crown; Thomas Hakes; Bonnie Reichman; David Lebwohl; Theresa Gilewski; Anto
π
Article
π
1993
π
John Wiley and Sons
π
English
β 345 KB
π 2 views
## Background: High-dose chemotherapy with hematopoietic support produces high rates of response in metastatic breast cancer. to facilitate new high-dose regimens there is a need to identify active agents with toxicity limited to hematopoietic suppression. cisplatin/etoposide is a highly active reg